Drugs that contain Metformin Hydrochloride; Saxagliptin Hydrochloride
1. Kombiglyze Xr patents expiration
KOMBIGLYZE XR's oppositions filed in EPO
KOMBIGLYZE XR Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 7 months from now) | |
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 7 months from now) | |
Market Authorisation Date: 05 November, 2010
Treatment: Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellit...
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage
KOMBIGLYZE XR family patents
